FDA panel votes to keep Avandia on shelves despite risks
Although evidence indicates that the diabetes drug Avandia causes an increased risk of heart attack, FDA advisers suggested that it stay on the market. The advisers said the drug packaging should include what is called a "black-box" warning to call patients' attention to the drug's risks.
The widely used diabetes drug Avandia should remain on the market, government health advisers overwhelmingly recommended Monday, saying evidence of an increased risk of heart attack doesn't merit removal.
The nonbinding recommendation to the Food and Drug Administration came on a 22-1 vote by the panel.
